четверг, 19 мая 2016 г.

FDA OKs immunotherapy drugs for bladder, blood cancers

FDA OKs immunotherapy drugs for bladder, blood cancers


U.S. regulators have approved the first drug for bladder cancer that harnesses the body's immune system, the first major advance in three decades against the most common type of bladder cancer. Tecentriq won accelerated approval Wednesday from the Food and Drug Administration for treating patients with advanced urothelial cancer after chemotherapy stops helping them - a point when most usually die within about six months.



from Biotech News